Biotechnology

Arbutus Pharma

Arbutus Pharma released FY2026 Q1 earnings on May 13 (EST), actual revenue USD 179.13 M (forecast USD 1.099 M), actual EPS USD 0.8699 (forecast USD -0.0201)

Arbutus Biopharma reports Q1 2026 net income of $169.7 million

Arbutus Pharma released FY2025 Q4 earnings on March 23 (EST), actual revenue USD 1.051 M (forecast USD 605.18 K), actual EPS USD -0.0195 (forecast USD -0.0354)

Arbutus Pharma released FY2025 earnings on March 23 (EST), actual revenue USD 14.08 M (forecast USD 13.79 M), actual EPS USD -0.1748 (forecast USD -0.1919)

European Patent Office Revokes Albimmune's Patent

Arbutus Pharma released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 529 K (forecast USD 941.22 K), actual EPS USD -0.0403 (forecast USD -0.0298)

Arbutus Pharma released FY2025 9 Months earnings on November 13 (EST), actual revenue USD 13.03 M, actual EPS USD -0.1589

Arbutus Biopharma Makes Progress in Chronic Hepatitis B Treatment

Arbutus Biopharma to Present New Clinical Data at AASLD Liver Meeting

Arbutus Pharma released FY2025 Semi-Annual Earnings on August 6 (EST), with actual revenue of USD 12.5 M and EPS of USD -0.12

Arbutus Pharma released FY2025 Q2 earnings on August 6 (EST), actual revenue USD 10.74 M (forecast USD 1.615 M), actual EPS USD 0.0099 (forecast USD -0.0483)

Arbutus Biopharma Corp Reacquires IMDUSIRAN Rights in Greater China

Albutus Biopharma Regains Rights to Imdusiran in China

Bank of America Increases Stake in Arbutus Biopharma

Arbutus Pharma released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 1.764 M (forecast USD 1.597 M), actual EPS USD -0.1299 (forecast USD -0.1037)

Arbutus Biopharma Sees 20% Revenue Growth but Expanded Net Loss in Q1 2025

Albuitus Biopharma Displays Clinical Trial Data for HBV Treatment Drugs

Arbutus Biopharma Corp Expected to Report EPS Loss of 10 Cents

Arbutus Pharma released FY2024 Q4 earnings on March 27 (EST), actual revenue USD 1.574 M (forecast USD 1.538 M), actual EPS USD -0.066 (forecast USD -0.0785)

Arbutus Pharma released FY2024 earnings on March 27 (EST), actual revenue USD 6.171 M (forecast USD 6.076 M), actual EPS USD -0.3767 (forecast USD -0.3815)

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

MetaVia

Vida Global

MicroAlgo

Tradr 2X Long XNDU Daily ETF

MRNA

ABUS

Arbutus Biopharma (ABUS) reported Q1 2026 revenue of $179.1M and net income of $169.7M, primarily due to a $178.7M license payment from the Genevant/Moderna settlement. The adjusted loss was $0.05 per share, slightly worse than the expected $0.03. Revenue decreased by 40% year-over-year. The stock has declined approximately 4.2% this quarter and 10.4% year-to-date, with a 12-month price target of $5.00.

TradingView

Moderna

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

VanEck Biotech ETF

iShares US Pharma

ALPS Medical Breakthrough

VG Health

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Key facts: ABUS Q1 $179.1M revenue; $169.7M net, $0.05 adj loss

Earnings Watch

Arbutus Pharma | 10-Q: FY2026 Q1 Revenue: USD 179.13 M

Arbutus Pharma | 8-K: FY2026 Q1 Revenue: USD 179.13 M

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | ABUS Stock News

StockTitan

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | ABUS Stock News

GEVO

BIRD

MIND

QDEL

SFST

U.S. stock futures rose, but several stocks, including QuidelOrtho, MIND Technology, and Allbirds, fell in pre-market trading. QuidelOrtho shares dropped 19.4% to $14.09 after reporting weaker-than-expected preliminary revenue of $615-$620 million for Q1 2026, attributed to a decline in respiratory illness visits and slower sales. Allbirds fell 31.9% after a significant rise the previous day. Other notable declines included MIND Technology down 19.2%, Arbutus Biopharma down 15.2%, and Gevo down 7.4%.

benzinga_article

Allbirds

MIND Techonology

QuidelOrtho

Southern First Bancshare

Dow Jones Industrial Average

MMTEC

Alto Ingredients

Wheels Up Experience

CECO Environmental

Almonty Industries

WHEELS UP EXPERIENCE INC

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Arbutus Pharma(ABUS.US)

Key facts: ABUS Q1 $179.1M revenue; $169.7M net, $0.05 adj loss

Arbutus Pharma | 10-Q: FY2026 Q1 Revenue: USD 179.13 M

Arbutus Pharma | 8-K: FY2026 Q1 Revenue: USD 179.13 M

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | ABUS Stock News

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session